The company develops orally administered, minimally absorbed drugs that act locally in the gastrointestinal tract, addressing diseases such as inflammatory bowel disease, type 2 diabetes, celiac disease, GI acute radiation syndrome, and oral mucositis. Their lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease, offering potentially improved safety and efficacy over existing therapies. Ataxia Biologics aims to overcome limitations of traditional antibody therapeutics by delivering antibodies directly to the GI tract through their proprietary oral antibody platform.